As reported on Forbes, a class of drugs first introduced to combat HIV is now demonstrating unexpected promise for patients with rare genetic and mitochondrial disorders. Once designed to block…
Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…
By Thresa Giles, CEO — Hope & Help Center of Central Florida Since HIV was first identified in 1983, there has been a growing, persistent stigma surrounding it. People have…
In a significant advancement for HIV prevention, the Centers for Disease Control and Prevention (CDC) has issued a strong recommendation for Yeztugo (lenacapavir), Gilead Sciences’ long-acting, twice-yearly pre-exposure prophylaxis (PrEP)…
South Africa is on the brink of a major shift in HIV prevention, with plans to introduce lenacapavir—a twice-yearly injectable—at select public clinics by April 2026. As reported by All…
The landscape of HIV treatment continues to evolve, and a significant milestone has just been reached with the FDA’s approval of Rukobia (fostemsavir), a novel therapy from ViiV Healthcare. Reported…
According to a story from Forbes, Joe Rogan's hit podcast "The Joe Rogan Experience," which is the most popular podcast on Spotify and commands an enormous following, has been no…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
